Remove Genetics Remove Hormones Remove Radiology
article thumbnail

Patient Safety and Radiopharmaceuticals Administration: Minimizing Radiation Exposure and Risks

Worldwide Clinical Trials

Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation. Hormonal Status : A body’s hormones, such as levels of reproductive hormones and thyroid function, can impact tissue responses to radiation therapy.

Hormones 130
article thumbnail

Scrutinizing the West Syndrome Market Space from Growth Perspectives

Delveinsight

It can be due to the previous existence of brain damage signs (psychomotor retardation, neurologic signs, radiologic signs, or other types of seizures) or on the basis of etiology that is characterized by a lack of previous signs of brain damage. There are many different causes of epileptic spasms. before the onset of the spasm.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women’s Health Clinical Trials: Clinical Innovations, Opportunities and Considerations

XTalks

Misconceptions and Biases: Despite the known physiologic, metabolic and hormonal differences between men and women, there remains a long-standing misconception that drugs exert the same effects in both men and women. There is a growing recognition of the need for inclusive research that accurately reflects the diverse experiences of women.

article thumbnail

Hypoxia-Inducible Factor-2 Alpha (HIF-2?) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

The Pharma Data

Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. The major efficacy endpoint for the treatment of VHL-associated RCC was ORR measured by radiology assessment using RECIST v1.1 months (range, 2.8 as assessed by IRC. Lactation.

article thumbnail

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

Delveinsight

Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. X-linked myotubular myopathy (XLMTM) is a rare genetic neuromuscular disorder and leads to muscle weakness, respiratory failure, and early death. mg and norethindrone acetate (0.5 mg) in the US and Canada.

Trials 52